The liver participates in a multitude of metabolic functions that are critical for sustaining human life. Despite constant encounters with antigenic-rich intestinal blood, oxidative stress, and metabolic intermediates, there is no appreciable immune response. Interestingly, patients undergoing orthotopic liver transplantation benefit from a high rate of graft acceptance in comparison to other solid organ transplant recipients. In fact, cotransplantation of a donor liver in tandem with a rejection-prone graft increases the likelihood of graft acceptance. A variety of players may account for this phenomenon including the interaction of intrahepatic antigen-presenting cells with CD4
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The liver participates in a multitude of metabolic functions that are critical for sustaining human life. Despite constant encounters with antigenic-rich intestinal blood, oxidative stress, and metabolic intermediates, there is no appreciable immune response. Interestingly, patients undergoing orthotopic liver transplantation benefit from a high rate of graft acceptance in comparison to other solid organ transplant recipients. In fact, cotransplantation of a donor liver in tandem with a rejection-prone graft increases the likelihood of graft acceptance. A variety of players may account for this phenomenon including the interaction of intrahepatic antigen-presenting cells with CD4
1 T cells and the preferential induction of forkhead box P3 (Foxp3) expression on CD4 1 T cells following injurious stimuli. Ineffective insult management can cause chronic liver disease, which manifests systemically as the following: antibody-mediated disorders, ineffective antiviral and antibacterial immunity, and gastrointestinal disorders. These sequelae sharing the requirement of CD4 1 T cell help to coordinate aberrant immune responses. In this review, we will focus on CD4 1 T cell help due to the shared requirements in hepatic tolerance and coordination of extrahepatic immune responses. Overall, intrahepatic deviations from steady state can have deleterious systemic immune outcomes and highlight the liver's remarkable capacity to maintain a balance between tolerance and inflammatory response while simultaneously being inundated with a panoply of antigenic stimuli.
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Anatomic location can have a crucial influence on T cell subset differentiation and function. (1, 2) The specialized functions of the liver create a unique microenvironment in which T cells are exposed to different environmental stimuli in comparison to other peripheral lymphoid organs. The liver is a vital site of nonredundant metabolic functions required for sustaining life. As such, it is equipped to manage a certain degree of inflammation such that normal metabolic functions may continue uninterrupted. This unique property reputes the liver as a "tolerogenic site" due to constant encounters with a wide array of self-antigens, food antigens, gut commensals, oxidative stress, and metabolites without any appreciable immunological consequences or tissue damage. (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) This is due to a complex collaboration of liver antigen-presenting cells (APCs), lymphoid cells, and nonparenchymal cells at steady state.
The liver is composed of distinct tissue-resident lymphoid and nonlymphoid cells that do not appear in peripheral counterparts. (8, 14) In both humans and mice, the liver lymphoid compartment is enriched in nonconventional immune cell subsets including natural killer cells and T cell receptor (TCR) cd 1 T cells. (4, 8) The collective actions of these lymphocytes critically contribute to early immune responses to pathogens, antitumor responses, and maintenance of liver homeostasis. Interactions of intrahepatic CD4 1 T cells and liver-resident APCs such as dendritic cells (DCs), Kupffer cells (KCs), and liver sinusoidal endothelial cells (LSECs) help facilitate tolerance. In comparison to peripheral counterparts, intrahepatic APCs maintain an immature phenotype and preferentially produce tolerogenic cytokines, such as interleukin (IL) 10, following the encounter of antigens. (6, 12, 15, 16) The interaction of intrahepatic APCs and T cells has been implicated as a mechanism of maintaining peripheral tolerance to self-antigens, food antigens, and allografts. (13, (17) (18) (19) Conversely, the poor immunogenicity of the liver microenvironment is associated with permissiveness to chronic hepatotropic infections and weak antitumor responses. (6, 8, 11) Because of the composition of the liver lymphoid and nonlymphoid compartments and the multitude of metabolic and immunologic functions in which they participate, the cells in the liver form a distinct microenvironment. Thus, the events within the intrahepatic milieu could potentially hold the key to treating a variety of immunological disorders and management of graft acceptance.
The overall tolerogenic nature of the liver is exemplified in the context of solid organ transplantation. For example, early studies of liver transplantation in pigs revealed spontaneous tolerance of the engrafted liver. (20) In fact, donor-matched liver transplantation in tandem with a rejection-prone graft, such as the kidney, can halt rejection episodes. (21) As a result, many patients do not require overly aggressive immunosuppressive regimens following orthotopic liver transplantation. (22) (23) (24) Livergraft rejection episodes are largely T cell-mediated, (5, (25) (26) (27) and there have been substantial efforts in understanding how the intrahepatic T cell immune responses can facilitate tolerance to allografts. Although pretransplant indicators of graft acceptance rates are not well defined, there is evidence that immune responses within the liver may contribute to systemic tolerance of foreign antigens-including allografts. (28, 29) Moreover, perturbations within the liver microenvironment, such as chronic fibrosis, can manifest extrahepatically as inflammatory and autoimmune disorders, largely T cell-mediated phenomena. (3, 12, (30) (31) (32) Here, we will review the influence of the liver microenvironment particularly on CD4
1 T cell subset help and associated alterations during liver disease and how it can contribute to breaks in tolerance. Overall, a better understanding of the role of the intrahepatic microenvironment in transplant outcomes will inform clinical decisions surrounding transplantation.
Extrahepatic Manifestations of Liver Injury and Influence on Clinical Decisions Surrounding Transplant
Despite different mechanisms of eliciting liver damage, nearly all liver insults converge at hepatic stellate cell (HSC) activation, which initiates fibrosis. (33) When provoked, HSCs become activated and secrete collagen, extracellular matrix proteins, profibrotic cytokines, chemokines, and retinoic acid to begin the tissue repair process. Once the insult is resolved, this process reverses as scar tissue is replaced by healthy tissue. (34) This process, fibrosis-reversible liver scarring, initiates the liver wound healing process and functions to siphon the insult away from healthy tissue. (33, 34) The increased instance of CD4 1 forkhead box P3 (Foxp3) 1 T cells in the fibrotic liver (35) coexists with aberrant B cell activation that is often accompanied by systemic antibody-mediated autoimmunity during chronic liver disease. (3, 30, 36, 37) Although these CD4 1
Foxp3
1 T cells are capable of CD8 1 T cell suppression, our own studies have defined a novel fibrosisinduced CD4
1 Foxp3 1 T cell subpopulation that promotes immunoglobulin-mediated extrahepatic symptoms of liver disease through CD40L expression ( Fig.  1) . (38) In addition, during liver injury, activated hepatocytes produce complement proteins, which are key mediators of liver repair. (39) (40) (41) Consequently, studies in human peripheral blood mononuclear cells have found that stimulation through CD46, the complement receptor, in the presence of professional APCs (ie, monocytes and DCs) and inflammatory cytokines can also induce Foxp3 expression on CD4 1 T cells. (42, 43) These so-called complement regulatory T cells (Tregs) can also suppress CD8
1 T cell responses, (43) while stimulating antibody production from B cells via CD40L expression. (42) This may represent a pathway in which existing liver injury in endstage kidney disease may predispose the recipient to antibody-mediated rejection episodes. Interestingly, emerging clinical evidence suggests that targeting the complement pathway with eculizumab, a monoclonal antibody against complement protein C5 (C5), attenuates acute antibody-mediated rejection episodes in the setting of transplantation. (44) The risk of antibody-mediated rejection can be significantly reduced when kidney transplant recipients are simultaneously transplanted with a liver allograft from the same donor. (45) (46) (47) Early studies in rodent models suggest that liver-resident populations, such as KCs, contribute to absorption and subsequent clearance of alloreactive antibodies. (48, 49) In the clinic, simultaneous liverkidney transplantations (SLKTs) are performed in patients who experience renal nonrecovery during chronic liver disease. (46, 50) SLKT rates have increased since the implementation of the Model for End-Stage Liver Disease (MELD) scoring system. (46) The MELD criteria emphasize serum indicators of kidney function, such as creatinine, (51, 52) to inform clinical decisions surrounding SLKT candidacy (Fig. 2) . However, these criteria do not decouple kidney disease as a comorbidity of liver disease. In fact, some patients experience near complete renal recovery once liver disease is addressed with liver transplant alone. (53) (54) (55) Although MELD criteria and assessment of kidney function in liver transplant candidates may be a point of disconnect among centers, there are clear benefits of SLKT in patients with high levels of donor-specific antibodies prior to transplantation. (56) End-stage liver disease (ESLD)-related destruction of the intrahepatic microarchitecture, hemodynamic alterations, and loss of detoxification functions have been attributed to kidney disorders associated with ESLD. (52) Thus, any renal recovery following hepatic transplantation alone may simply be the outcome of successful engraftment and regained liver function. (56) In addition to physiologic perturbations, the intrahepatic milieu fundamentally changes in such a way that implicates aberrant immune responses such as constitutive antibody production. (38, 57) Accordingly, ESLD-related increases in serum antibody content and immune complexes can potentially accumulate and cause kidney damage. (27, 44) In either case, liver transplantation could conceivably reconstitute kidney function in ESLD patients as well as alleviate aberrant immune responses. 
Intrahepatic Immune Responses Govern Peripheral Tolerance to Food and Alloantigens

Hepatic CD4
1 T cells receive different cues than the peripheral CD4 1 T cells due to their interaction with liver-resident APCs and other nonparenchymal cells within the liver. Because the liver shares an estimated 70% of its blood supply with the gut via portal venous blood, the microenvironment is continually bathed in microbial products, metabolites, and food antigens. (13) The liver has been implicated as a key anatomic site of maintaining peripheral tolerance via direct and indirect modulation of T cell responses. (11, 58) For instance, intrahepatic CD4
1 T cell help may be a determinant in responses to innocuous antigens, such as food versus allergy inducing stimuli. Early studies have demonstrated that the liver participates in tolerance to food antigens. (17, (59) (60) (61) For example, these experiments have found that diverting portal venous blood flow could ameliorate oral tolerance of ingested ovalbumin in na€ ıve mice. (61) This suggests that the context in which antigen is presented in the periphery versus intrahepatic presentation can differentially influence the quality and magnitude of the immune response. Thus, mechanisms of eliciting oral tolerance may be intrinsic to the liver.
Interestingly, clinical reports indicate that liver allograft donor-derived food allergies can be transferred to recipients. (62, 63) Clinical management of these new posttransplantation allergies employs T cell-based immunosuppressive strategies. (63) Studies in rodent models suggest that inducible regulatory T cells (iTregs) play an important role in the outcome responses to innocuous food antigens. (18, 19) iTreg generation is a consequence of intrahepatic presentation of antigen to CD4
1 T cells and is regarded as a mechanism of dampening the intrahepatic inflammation. (5, 9, 12, 64, 65) Combined, these studies highlight a putative role of intrahepatic presentation of food antigens to CD4
1 T cells as a tolerance mechanism that has yet to be explored.
Intrahepatic CD4
1
T Cell Priming
It is not clear what determines the outcome of hepatic tolerance. However, there is considerable evidence that liver-resident APCs and nonparenchymal cells participate in graft acceptance. (29, 66) Mixed lymphocyte reactions (MLRs) of LSECs presenting allo-antigens to CD8 1 T cells demonstrate an underappreciated role of LSECs tolerizing antigraft immunity even in complete major histocompatibility complex mismatch. (67) (68) (69) Furthermore, HSCs undergoing activation as a result of inflammatory events (70) promote increased Tregs via all-trans retinoic acid; this population can suppress immune-mediated injury to the graft. (65, 71) Another study by Morita et al. (72) suggested that regardless of which mechanisms are at play, tolerance of hepatic allografts requires interferon (IFN) c, a cytokine commonly associated with rejection. Using IFNc -/-mice, they found that the IFNc pathway in hepatic nonparenchymal cells is critical for suppressing rejection responses. Upon sensing inflammation, IFNc signaling on hepatic nonparenchymal cells led to increased programmed death 1 (PD-1) expression and other key mediators of apoptotic death of infiltrating CD8 1 T cells. (72) Although seemingly counterintuitive compared with peripheral compartments, these data suggest that episodes of acute inflammation trigger
FIG. 2.
Renal dysfunction due to ESLD-related immune aberrations. Typically, the destruction of the intrahepatic microarchitecture, hemodynamic alterations, and loss of detoxification functions have been attributed to kidney disorders associated with ESLD.
(52) (Top) The MELD criterion uses kidney function as a clinical decision-making tool for SLKT versus liver transplant alone. (Bottom) In some cases, liver transplant alone can rescue kidney functions (53) (54) (55) and thereby reduce the need for SLKT. This suggests that immune responses within the liver may affect the kidney and perhaps other peripheral organ functions.
immunomodulatory pathways aimed at limiting immune-mediated injury and allowing preservation of organ function. Altogether, these studies suggest that liver-intrinsic mechanisms contribute to the unusually high rate of graft acceptance.
Liver-resident DCs can critically influence CD4 1 T cell helper functions following antigen recognition and hence contribute to the net "tolerogenic" environment. Typically, upon recognition of microbial stimuli through toll-like receptors (TLRs), DCs become activated, mature, and gain the capacity to uptake antigens and initiate the immune response. Although peripheral DCs are anatomically sequestered from constant stimulation, this is not the case in the liver. (73) (74) (75) Because of the variety of microbial products contained in the portal venous blood flow, intrahepatic DCs have reduced TLR4 expression in comparison to their splenic counterparts. (76) This is advantageous in the context of maintaining the tolerogenic nature of the liver microenvironment because reduced TLR4 expression means that liver-resident DCs do not mature in response to normal levels of endogenous endotoxin. (76) The immunologic consequences of CD4 1 T cell priming by intrahepatic DCs preferentially result in an IL10-and IL4-mediated response to specifically induce regulatory and T helper (T h ) 2-like phenotypes. (76, 77) Splenic DCs on the other hand promote a more inflammatory response characterized by T h 1-type cytokine production and increased proliferative capacity. (76) In addition to DCs, liver resident macrophages, KCs, have been implicated in dampening CD4
1 T cell responses to cognate antigen. At steady state, KC stimulation of CD4 1 T cells also results in a decreased activation state in comparison to splenic DCs. (78) Interestingly, cocultures of CD4 1 T cells initially activated by splenic DCs could be suppressed by the addition of KCs via prostaglandin secretion. (78) These cells may function as an additional mechanism in which ongoing inflammation is more effectively managed within the liver.
LSECs are liver resident scavengers that take up systemic and/or circulating antigens and present them to intrahepatic lymphocytes. (79) During steady state, LSEC-primed transgenic CD4
1 T cells are less activated than those primed with cognate antigen by splenic DCs. (11, 16, 80) The in vivo significance of this finding was investigated using the ovalbuminmediated autoimmune hepatitis adoptive transfer model. (81) OT-II CD4 1 T cells and OT-I CD8
1
T cells carry a transgenic TCR specific for different ovalbumin peptides. Cotransfer of LSEC-primed OT-II CD4 1 T cells along with OT-I CD8 1 T cells (implicated in liver injury in this model) was sufficient to suppress the ongoing immune response and attenuate liver injury. (81) Although mechanisms that limit intrahepatic immune reactions occur at steady state, episodes of inflammation can result in enhanced immunogenic properties of liver APCs. Mouse models of both chemically induced and dietary insufficiency-mediated liver injury have demonstrated that KCs in particular lose expression of programmed death ligand 1 (PD-L1), a tolerogenic mediator that exerts its function through interactions with PD-1 to suppress the T cell response (12, 82) while gaining expression of the immunogenic CD80 molecule. (83) As a result, these KCs were able to stimulate immune-mediated liver injury through immunogenic priming of transgenic CD4
1 T cell help. (83) This work is one of the first demonstrations of in vivo consequences of enhanced immunogenicity acquired by KCs during liver injury. Aside from KCs, LSECs acquire immunogenicity that is postulated to be the result of the inflammatory environment within which they reside. (16) Instead of promoting an anergic and/or regulatory CD4 1 T cell phenotype, fibrotic liver LSECs gain capacity to stimulate CD4 1 T cell proliferation and activation. (16) Thus, fibrosis promotes an inflammatory shift in the liver microenvironment that fosters immunogenic alterations in liverresident APC populations, both phenotypically and functionally. More study is required to better understand how the newly acquired stimulatory capacity of liver APCs governs immune-mediated injury and such understanding would benefit both angles of liver fibrosis and transplantation.
Organ injury is inevitable during organ procurement from the donor; this is usually the result of ischemia/ reperfusion associated with transplantation. Ischemia/ reperfusion injury (IRI) is caused by the absence of blood flow (ischemia, anoxia) and subsequent reintroduction of blood in the tissue (reperfusion, reoxidation); even brief periods of IRI are an unavoidable consequence transplanting any organ from a donor into a recipient. Aside from transplantation, IRI occurs during other physiologic events such as myocardial infarction, stroke, and other vascular blockages. (84) Surprisingly, IRI-like injuries can occur, as during chronic liver disease, due to destruction of hepatic architecture associated with liver fibrosis. During steady state, the hepatic architecture permits relatively diffuse blood flow due to the fenestrated endothelial layer. (73, 75, 85) Disruption of hepatic blood flow results in glycogen consumption and consequent adenosine triphosphate depletion, (86) thereby perpetuating metabolic disturbance, accumulation of reactive oxygen species, and inflammation. (87) Together, IRI drives hepatic parenchymal cell death and subsequent alteration of intrahepatic architecture.
Perhaps the transient nature of lymphocyte interactions within the intrahepatic milieu contributes to the management of immune responses. Patients can experience increased portal blood pressure due to destruction of the hepatic architecture, which can limit blood flow. (73, 75, 85) As a result, interaction of infiltrating and resident populations can be prolonged and contribute to the exacerbation of inflammation or to the expansion of antigen-specific cell populations that would not otherwise become activated. (88) (89) (90) Thus, deviation from homeostatic architecture during liver fibrosis or IRI-associated tissue destruction may prolong interaction of intrahepatic CD4
1 T cells with APCs. These interactions can facilitate immunogenic priming of CD4 1 T cells as opposed to promoting a Treg function; this crosstalk may play a role in immunemediated graft injury. (91) Overall, much of the work aimed at elucidating antigen presentation to CD4 1 T cells in the liver employs transgenic T cells derived from the spleens of donor animals. The disparate outcomes following exposure to antigen in the presence of liver versus splenic DCs or KCs and LSECs highlights the critical role of organ resident populations on the outcome of a primary immune response. Under normal conditions, a lack of a T h 1-like response to cognate antigen is clearly beneficial for the liver in terms of limiting inflammation; however, this also makes the liver vulnerable to pathogens and permissive to tumor growth. (6, 8) Although the implications of liver inflammation and its effects on CD4 1 T cell priming are just starting to be elucidated, further studies defining liver-specific immune alterations in CD4
1 T cell helper function will inform novel strategies to manage chronic liver disease and graft acceptance.
Conclusion
CD4
1 T cell fate and effector functions are dictated by integration of environmental cues and costimulatory properties of APCs. The inflammatory and autoimmune manifestations (3, 12, (30) (31) (32) of liver disease suggest that the physiologic microenvironment critically contributes to systemic tolerance; perturbations can have deleterious consequences. Alterations in the liver microenvironment during fibrosis can facilitate activation of typically hyporesponsive liver-resident APCs, resulting in enhanced T cell priming. (16, 83) Considering the detrimental inflammatory outcomes, activation of intrahepatic APCs seems to reinvigorate or access populations of T cells that have been partitioned to the liver. Harnessing intrahepatic APC activation has important therapeutic potential for vaccination strategies against chronic hepatotropic infections and cancers that have evaded the immune system. Although this may be a long way off, modulation of the liver microenvironment has the potential to tap into CD4 1 T cells that would have otherwise been anatomically sequestered and nonresponsive. A clear understanding of the intrahepatic factors and outcomes of CD4 1 T cell-mediated adaptive immune responses could elicit novel therapeutics for liver diseases as well as autoimmune syndromes and cancers.
Because of the therapeutic effects of Treg transfer therapy strategies in experimental model systems (5, 18, 19, 92) and, more recently, clinical transplant settings, (93) it is reasonable to consider these approaches in controlling inflammatory extrahepatic symptoms of liver disease. (94) In principle, the transfer of Tregs can serve to limit immune-mediated injury to the inflamed liver. However, it is important to consider that the composition of the fibrotic liver microenvironment is permissive to pathogenic fate decisions. (42, 43, (95) (96) (97) As a result, Treg transfer therapies for liver diseases may indeed exacerbate the extrahepatic sequelae rather than curtail it. More investigation is necessary to predict the outcome of this approach.
The systemic consequences of liver diseases suggest a greater role for the liver in modulating peripheral homeostasis as well as an interconnection of the liver and other anatomic compartments. For example, the entire body's blood supply passes through the liver approximately 360 times per day, (98) and the liver sequesters antigen-rich intestinal blood components from circulation. (13) These scavenger functions of the liver may contribute to successful outcomes of SLKT in patients with high levels of donor-specific antibodies. (46) Therefore, it is plausible that the liver can be influenced by inflammation from other peripheral compartments, such as the gastrointestinal (GI) tract, or by consequences of peripheral IRI and vice versa. This is an active and exciting avenue and more likely these pathway connections will be elucidated soon as the field expands.
In summary, the liver is unlike any other anatomic compartment. It is responsible for metabolic functions, protein production, detoxification, regulation, and serves as a site of immunologic education. Although the liver has evolved to manage a certain degree of deviation, surpassing the "point of no return" has detrimental effects on immunologic tolerance as well as general health. These extrahepatic manifestations of disease implicate the underappreciated role of the liver as a rheostat for immunologic harmony.
